StageZero Life Sciences Ltd. announced that people throughout the Greater Toronto Area can now access the company's multi-cancer blood test ARISTOTLE. Built on StageZero's proprietary mRNA technology, ARISTOTLE is a next-generation test which simultaneously screens for multiple cancers from a single sample of blood. ARISTOTLE must be prescribed by a physician and is available through AVRT, the Company's comprehensive telehealth program which uses advanced diagnostics and physician supervision to help patients detect cancer in the earliest stages. Through AVRT, patients who have a molecular signature for cancer detected via ARISTOTLE are paired with a dedicated case manager, oncologist, and/or other healthcare professionals to guide them on next steps.